News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Qorvo (QRVO) is back in focus after its August 11 annual general meeting, where shareholders voted against a proposal that would have granted investors the right to act by written consent. See our latest analysis for Qorvo. Qorvo's share …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Walleye Capital LLC has initiated a new investment in CorVel Corp. (NASDAQ:CRVL), purchasing 52,915 shares valued at approximately $3.31 million, representing 0.10% of the company. Other institutional investors have also adjusted their holdings, with State Street Corp and Geode Capital Management LLC increasing their …
The average 12-month price target for Qorvo, Inc. (QRVO) stock has been raised by analysts from $89.67 to $92.62, with individual forecasts ranging from $80 to $105 per share. This new target implies a potential 6% downside from the August 14 closing price. The …
Renaissance Technologies LLC has acquired a new stake worth $1.19 million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), indicating growing institutional interest, with hedge funds now owning 46.64% of the company. Despite positive analyst sentiment and a "Moderate Buy" rating, recent earnings missed estimates, and HC …
Mirae Asset Global Investments Co. Ltd. increased its holdings in Qorvo, Inc. by 11.1% in the second quarter, bringing its total to 117,401 shares valued at $10.95 million. Despite this increased institutional interest, company insiders sold nearly 1.97 million shares, and analysts maintain a …
This article provides a detailed financial overview of Qorvo Inc (QRVO), including its current stock price, market capitalization, P/E ratios, and dividend information. It also presents analyst ratings, technical analysis indicators, and a company profile outlining its segments and market reach. The article also …
Qorvo, Inc. director Susan Louise Spradley was awarded 2,327 shares of common stock on August 12, 2026, as a compensation-related grant. This transaction, valued at $0.00 per share, increased her direct holdings to 14,351 shares. The Form 4 filing indicates this was a grant …
Qorvo, Inc. (QRVO) director Chris Koopmans was granted 2,327 shares of common stock at a price of $0.00 per share on August 12, 2026, as reported in a recent Form 4 filing. This compensation-related equity transaction increases his direct holdings to 6,160 shares of …
Qorvo stock is trading near the $100 mark, showing renewed buying interest following its annual meeting where shareholders elected all directors and approved executive compensation, signaling continuity in leadership. Investors are assessing the company's valuation against historical levels and peers, with a focus on …
Shares of Qorvo Inc. (QRVO) rose 1.61% to $98.24 on Wednesday, outperforming the broader market. This gain broke a two-day losing streak for the company's stock. The S&P 500 Index saw a slight increase, while the Dow Jones Industrial Average experienced a marginal decline …
This article analyzes Qorvo Inc. (NASDAQ: QRVO) using AI models, identifying a potential short setup with a favorable risk-reward ratio based on a mid-channel oscillation pattern. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance …
Assenagon Asset Management S.A. significantly reduced its stake in CorVel Corp. (NASDAQ:CRVL) by 48.5% during the second quarter, selling 95,906 shares and retaining 101,952 shares valued at approximately $6.4 million. Despite institutional investors collectively owning 51.36% of CRVL, company insiders also sold 13,249 shares …
This article announces that CorVel Corp (CRVL) filed a Form 8K on August 11, detailing significant events or changes within the company. The brief update from Investing.com provides the filing date and the company's stock symbol, along with its recent performance. No specific details …
CorVel Corporation shareholders re-elected six directors to serve until the 2027 annual meeting and ratified the appointment of Haskell & White LLP as their independent registered public accounting firm for the fiscal year ending March 31, 2027. Additionally, shareholders approved the compensation of the …
CorVel Corporation (NASDAQ: CRVL) shareholders approved all three proposals at their 2026 annual meeting on August 6, 2026. This included the election of six directors, the ratification of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending …
Mizuho Securities has reiterated its Buy rating for Corvus Pharmaceuticals (CRVS.US) and maintained its price target at $30. This indicates a continued positive outlook from the firm regarding the company's stock performance.
The Manufacturers Life Insurance Company significantly increased its stake in Corvus Pharmaceuticals (NASDAQ:CRVS) by 481.7% in Q1, purchasing 84,282 shares to bring its total holdings to 101,779 shares valued at $1.49 million. Other institutional investors also expanded their positions, contributing to hedge funds and …
Covestro has announced its participation in the Kollert research project — a German publicly funded, interdisciplinary consortium dedicated to developing recyclable product concepts for automotive lighting, mechatronic and electronic components. The three-year project, funded by the German Federal Ministry for Research, Technology and Space …
Sharemaestro market context Price below Trend Line 52 weeks -22.2%Qorvo Inc. (QRVO) stock fell 2.10% on Monday, closing at $97.00. This underperformance occurred during a generally poor trading session where the S&P 500 Index and Dow Jones Industrial Average also saw slight declines. The stock's drop ended a four-day winning streak.
Corvus Pharmaceuticals (CRVS) reported a wider Q2 2026 net loss, leading to a recent share price pullback despite strong longer-term momentum. Analysts have a consensus price target of $35, suggesting the stock is undervalued based on future earnings and growth assumptions, though its current …
Eighteen brokerages have issued a consensus "Hold" rating for Qorvo, Inc. (NASDAQ:QRVO), with an average 12-month price target of $94.00, which is below its current trading price of $99.08. Despite beating quarterly earnings and revenue estimates, the company experienced a 4.2% year-over-year revenue decline. …
This article provides an earnings forecast for CorVel Corp (CRVL), detailing future EPS and revenue growth estimates. It includes current stock information such as market cap and P/E ratio, alongside a peer comparison table with ratings and analyst counts for several healthcare companies. The …
This article analyzes Corvel Corp. (CRVL) through the lens of quantitative research, highlighting its impact on rotational strategy timing. It identifies a positive near-term sentiment for CRVL that may be shifting, with no clear price positioning signal but compelling upside potential due to the …
Corvus Pharmaceuticals (NASDAQ:CRVS) has received a "Moderate Buy" average recommendation from eight research firms, with an average 12-month price target of $33.33, significantly higher than its current share price of $13.92. Despite a recent quarterly loss that missed analyst expectations, institutional ownership is strong, …
Search by ticker symbol or company name and select a result to open its chart.